紫杉醇联合顺铂、5-氟尿嘧啶治疗晚期食管癌近期疗效观察

Clinical observation of paclitaxel cisplatin combined with fluorouracil therapy with advanced esophageal cancer

目的观察紫杉醇联合顺铂（DDP）加亚叶酸钙（CF）和5-氟尿嘧啶（5-FU）方案治疗晚期食管癌的近期疗效及安全性。方法观察55例晚期食管癌患者,PTX 135~175 mg·m-2,静脉滴注3 h,d1,DDP 20 mg·m-2d1~d4、CF 0.2g.m-2d2~d3、5-FU2.0g.m-2持续静滴46 h（d2~d3）,3周一疗程,至少进行2个周期后评价。结果 55例患者中可评价疗效的患者55例,其中CR 2例,占3.6%;PR 29例,占52.7%;有效率（CR＋PR）为56.3%;SD 15例,占27.3%;PD 9例,占16.4%。临床毒副反应为骨髓抑制,消化道反应,口腔黏膜炎,周围神经毒性。结论紫杉醇联合顺铂、5-氟尿嘧啶方案对晚期食管癌疗效肯定,毒副反应轻,值得临床推广应用。

Aim To evaluate the efficacy and toxicity of paclitaxel and cisplatin plus CF/fluorouracil regimen treatment in the advanced esophageal cancer.Methods 55 patients of advanced esophageal cancer were treated.The treatment schedule consisted of paclitaxel iv 135~175 mg·m-2,d1,and cisplatin 20 mg·m-2,iv,d1~d4 plus CF 0.2 g·m-2,iv,d2~d3,and fluorouracil 2 g·m-2,civ for 46 h,d2~d3 were administered every three weeks.Results All 55 patients were eligible for clinical response evaluation.The overall response rate was 56.3%,including 2 cases of CR,29 cases of PR,15 cases of SD and 9 cases of PD respectively.The major side-effects were neutropenia,gastrointestinal reaction,oral mucositis,peripheral neurotoxicity.Conclusion Paclitaxel and cisplatin plus CF / fluorouracil regimen has a palliative role in patients with a dvanced esophageal cancer.